Buskova J, Klaschka J, Sonka K, Nevsimalova S (2010) Olfactory dysfunction in narcolepsy with and without cataplexy. Sleep Med 11(6):558–561. doi:10.​1016/​j.​sleep.​2010.​01.​009 CrossRefPubMed

Caillol M, Aioun J, Baly C, Persuy MA, Salesse R (2003) Localization of orexins and their receptors in the rat olfactory system: possible modulation of olfactory perception by a neuropeptide synthetized centrally or locally. Brain Res 960(1–2):48–61CrossRefPubMed

Danielyan L, Schafer R, von Ameln-Mayerhofer A, Buadze M, Geisler J, Klopfer T, Burkhardt U, Proksch B, Verleysdonk S, Ayturan M, Buniatian GH, Gleiter CH, Frey WH 2nd (2009) Intranasal delivery of cells to the brain. Eur J Cell Biol 88(6):315–324. doi:10.​1016/​j.​ejcb.​2009.​02.​001 CrossRefPubMed

Dauvilliers Y, Baumann CR, Carlander B, Bischof M, Blatter T, Lecendreux M, Maly F, Besset A, Touchon J, Billiard M, Tafti M, Bassetti CL (2003) CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. J Neurol Neurosurg Psychiatry 74(12):1667–1673PubMedCentralCrossRefPubMed

Deadwyler SA, Porrino L, Siegel JM, Hampson RE (2007) Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci (the official journal of the Society for Neuroscience) 27(52):14239–14247. doi:10.​1523/​JNEUROSCI.​3878-07.​2007 CrossRef

Dhuria SV, Hanson LR, Frey WH 2nd (2009a) Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system. J Pharm Sci 98(7):2501–2515. doi:10.​1002/​jps.​21604 CrossRefPubMed

Dhuria SV, Hanson LR, Frey WH 2nd (2009b) Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous system. J Pharmacol Exp Therapeutics 328(1):312–320. doi:10.​1124/​jpet.​108.​145565 CrossRef

Dhuria SV, Hanson LR, Frey WH 2nd (2010) Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 99(4):1654–1673. doi:10.​1002/​jps.​21924 PubMed

Djupesland PG, Messina JC, Mahmoud RA (2014) The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview. Therapeutic delivery 5(6):709–733. doi:10.​4155/​tde.​14.​41 CrossRefPubMed

Estabrooke IV, McCarthy MT, Ko E, Chou TC, Chemelli RM, Yanagisawa M, Saper CB, Scammell TE (2001) Fos expression in orexin neurons varies with behavioral state. J Neurosci (the official journal of the Society for Neuroscience) 21(5):1656–1662

Field P, Li Y, Raisman G (2003) Ensheathment of the olfactory nerves in the adult rat. J Neurocytol 32(3):317–324. doi:10.​1023/​B:​NEUR.​0000010089.​37032.​48 CrossRefPubMed

Fujiki N, Yoshida Y, Ripley B, Mignot E, Nishino S (2003) Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep 26(8):953–959PubMed

Fulda S, Schulz H (2001) Cognitive dysfunction in sleep disorders. Sleep Med Rev 5(6):423–445. doi:10.​1053/​smrv.​2001.​0157 CrossRefPubMed

Ganjavi H, Shapiro CM (2007) Hypocretin/Orexin: a molecular link between sleep, energy regulation, and pleasure. J Neuropsychiatry Clin Neurosci 19(4):413–419. doi:10.​1176/​appi.​neuropsych.​19.​4.​413 CrossRefPubMed

Gorojankina T, Grebert D, Salesse R, Tanfin Z, Caillol M (2007) Study of orexins signal transduction pathways in rat olfactory mucosa and in olfactory sensory neurons-derived cell line Odora: multiple orexin signalling pathways. Regul Pept 141(1–3):73–85. doi:10.​1016/​j.​regpep.​2006.​12.​012 CrossRefPubMed

Groothuis DR, Vavra MW, Schlageter KE, Kang EW, Itskovich AC, Hertzler S, Allen CV, Lipton HL (2007) Efflux of drugs and solutes from brain: the interactive roles of diffusional transcapillary transport, bulk flow and capillary transporters. J Cereb Blood Flow and Metab: Official J Int Soc Cereb Blood Flow Metabolism 27(1):43–56. doi:10.​1038/​sj.​jcbfm.​9600315 CrossRef

Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S, Benham CD, Taylor SG, Routledge C, Hemmati P, Munton RP, Ashmeade TE, Shah AS, Hatcher JP, Hatcher PD, Jones DN, Smith MI, Piper DC, Hunter AJ, Porter RA, Upton N (1999) Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci USA 96(19):10911–10916PubMedCentralCrossRefPubMed

Hallschmid M, Benedict C, Schultes B, Fehm HL, Born J, Kern W (2004) Intranasal insulin reduces body fat in men but not in women. Diabetes 53(11):3024–3029CrossRefPubMed

Hanson LR, Martinez PM, Taheri S, Kamsheh L, Mignot E, Frey WH 2nd (2004) Intranasal administration of hypocretin 1 (orexin A) bypasses the blood-brain barrier & targets the brain: a new strategy for the treatment of narcolepsy. Drug Delivery 4(4)

Heier MS, Evsiukova T, Vilming S, Gjerstad MD, Schrader H, Gautvik K (2007) CSF hypocretin-1 levels and clinical profiles in narcolepsy and idiopathic CNS hypersomnia in Norway. Sleep 30(8):969–973PubMedCentralPubMed

Hermens WA, Belder CW, Merkus JM, Hooymans PM, Verhoef J, Merkus FW (1992) Intranasal administration of estradiol in combination with progesterone to oophorectomized women: a pilot study. Eur J Obstet Gynecol Reprod Biol 43(1):65–70CrossRefPubMed

Illum L (2000) Transport of drugs from the nasal cavity to the central nervous system. Eur J pharmaceutical Sci: Official J Eur Fed Pharm Sci 11(1):1–18CrossRef